StreetInsider.com News Articles

Scienture reports $1.22M in preliminary Q3 2026 revenue

Tue, 13 Oct 2026 08:05:53 -0400

Scienture Holdings (NASDAQ: SCNX) reported preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing a 256% sequential increase from approximately $344,000 in the second quarter of 2026, according to a press release from the company.

The revenue growth was attributed to two factors: the commercial launch of Rezenopy, a naloxone hydrochloride nasal spray indicated for emergency treatment of opioid overdose, in August 2026, including initial wholesale shipments, and continued sales growth of Arbli, a liquid formulation of losartan used to treat hypertension. Wholesale unit sales of Arbli increased 74% sequentially, with the company citing

Scienture reports $1.22M in preliminary Q3 2026 revenue

Tue, 13 Oct 2026 08:05:53 -0400

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

Tue, 13 Oct 2026 08:05:00 -0400

Continued Arbli^™ sales growth, combined with REZENOPY^™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth

Arbli^™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial expansion

COMMACK, NY, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced preliminary, unaudited revenue of approximately

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

Tue, 13 Oct 2026 08:05:00 -0400

Continued Arbli^™ sales growth, combined with REZENOPY^™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth

Arbli^™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial expansion

Form 8-K Scienture Holdings, Inc. For: Oct 05

Wed, 07 Oct 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20261007/27162069.html

Scienture's Arbli added to formularies at three pediatric hospitals

Fri, 02 Oct 2026 08:06:57 -0400

Scienture Holdings (NASDAQ: SCNX) announced that its Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formularies of three U.S. pediatric academic medical centers and hospitals, according to a company statement.

Arbli is a ready-to-use oral suspension formulation of losartan potassium indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. The product does not require extemporaneous pharmacy compounding and is stored at room temperature with a shelf life of 24 months.

The company states that the U.S. losartan market represents approximately $219 million in annual sales and roughly 72 million prescriptions

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Fri, 02 Oct 2026 08:05:00 -0400

Major Institutional Formulary Win Expands Arbli^™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially

Arbli^™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually

COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli^™ (losartan potassium) Oral Suspension, 10 mg/mL has been

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Fri, 02 Oct 2026 08:05:00 -0400

Major Institutional Formulary Win Expands Arbli^™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially

Arbli^™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually

Scienture Holdings announces 1-for-25 reverse stock split

Wed, 30 Sep 2026 16:05:10 -0400

Scienture Holdings, Inc. (NASDAQ: SCNX) announced a 1-for-25 reverse stock split of its common stock, set to take effect before markets open on October 5, 2026.

As of September 30, 2026, the company has 41,064,146 shares of common stock issued and outstanding. Following the reverse stock split, Scienture expects approximately 1,642,565 shares to remain issued and outstanding.

The company's stock will continue trading on the Nasdaq Capital Market under the ticker symbol "SCNX" and will begin trading on a split-adjusted basis when the market opens on October 5, 2026. The new CUSIP number for the common stock will be 80880X203.

Every 25 shares

Scienture Holdings, Inc. Announces Reverse Stock Split

Wed, 30 Sep 2026 16:05:00 -0400

COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is expected to take effect before markets open on Monday, October 5, 2026. The Company’s common stock will continue to

Scienture Holdings, Inc. Announces Reverse Stock Split

Wed, 30 Sep 2026 16:05:00 -0400

Form 8-K Scienture Holdings, Inc. For: Sep 14

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091848.html

Scienture signs deal to sell Rezenopy at 2,000 addiction clinics

Tue, 22 Sep 2026 08:16:51 -0400

Scienture Holdings (NASDAQ: SCNX) announced that its subsidiary, Scienture LLC, has entered into an exclusive sales, marketing, and distribution agreement with an unnamed distribution partner to supply Rezenopy (naloxone hydrochloride nasal spray 10 mg/0.11 mL) to opioid and substance-use disorder treatment centers across the United States.

Under the agreement, Rezenopy will be distributed through the partner's network of approximately 2,000 opioid treatment program (OTP) clinics and other addiction treatment centers nationwide. The distribution partner was not identified in the announcement.

Scienture said it will continue to commercialize Rezenopy outside the addiction treatment center market through wholesaler agreements, group purchasing organizations, and other

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Tue, 22 Sep 2026 08:15:00 -0400

Agreement provides dedicated commercial channel for REZENOPY^™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States

According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units

COMMACK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Tue, 22 Sep 2026 08:15:00 -0400

According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units

Form DEF 14A Scienture Holdings, Inc. For: Sep 18

Fri, 18 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260918/27080560.html

Form 8-K Scienture Holdings, Inc. For: Sep 14

Mon, 14 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260914/27058426.html

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

Wed, 09 Sep 2026 08:55:00 -0400

Management to Highlight Growing Commercial Momentum of Arbli^™ and the Commercial Launch of REZENOPY^™

COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14 – 16, 2026 in New York City.

During the presentation, management

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

Wed, 09 Sep 2026 08:55:00 -0400

Management to Highlight Growing Commercial Momentum of Arbli^™ and the Commercial Launch of REZENOPY^™

During the presentation, management

Form 8-K Scienture Holdings, Inc. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956178.html

Form 8-K Scienture Holdings, Inc. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956178.html

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Fri, 14 Aug 2026 08:08:00 -0400

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base

Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio